Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Unicycive Therapeutics Inc UNCY

Healthcare Biotechnology
Unicycive Therapeutics, Inc. is a biotechnology company that is developing treatments for certain medical conditions. Its programs are focused on kidney disease, an area that has the potential to offer medical benefits. Its development programs are focused on two novel therapies: Oxylanthanum Carbonate, and UNI 494. Oxylanthanum Carbonate is a novel investigational phosphate binding agent being... see more

Recent & Breaking News (NDAQ:UNCY)

Unicycive Issued Notice of Acceptance to Initiate Phase 1 Study of UNI-494 Following Review of Clinical Trial Application by the Medicines and Healthcare Products Regulatory Agency in the United Kingdom

GlobeNewswire December 22, 2022

Unicycive Therapeutics, Inc. Interview to Air on Bloomberg U.S. on the RedChip Money Report(R)

Accesswire December 9, 2022

Planned Government Move To Expand Access To Drugs For End-Stage Renal Disease Patients Could Shine The Spotlight On Unicycive

TheNewsWire December 8, 2022

Unicycive to Participate in Upcoming Investor Conferences

GlobeNewswire November 28, 2022

Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Geographic Atrophy

GlobeNewswire November 21, 2022

Unicycive Announces Third Quarter Financial Results and Provides Business Update

GlobeNewswire November 14, 2022

Unicycive Completes Enrollment of Pivotal Bioequivalence Study for RENAZORB(TM) (lanthanum dioxycarbonate), an Investigational Treatment for Hyperphosphatemia in Chronic Kidney Disease (CKD) Patients on Dialysis

GlobeNewswire November 10, 2022

Unicycive’s Doug Jermasek, EVP-Corporate Development Discusses the Importance of Medication Compliance and the Issues with Pill Burden

TheNewsWire November 8, 2022

Unicycive to Showcase Pipeline of Innovative Product Candidates at American Society of Nephrology's Kidney Week 2022

GlobeNewswire October 26, 2022

Mighty Mitochondria: This Company is Developing A Novel Drug for Kidney Disease By Targeting The Powerhouse Of Human Cells

TheNewsWire October 12, 2022

Unicycive Therapeutics to Present at Roth Inaugural Healthcare Opportunities Conference

GlobeNewswire September 29, 2022

How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication

TheNewsWire September 23, 2022

Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Acute Kidney Injury (AKI)

GlobeNewswire September 7, 2022

Unicycive Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

GlobeNewswire September 6, 2022

Unicycive Announces Multiple Abstracts Selected for Presentation at American Society of Nephrology's Kidney Week 2022

GlobeNewswire August 24, 2022

Unicycive Announces Second Quarter Financial Results and Provides Business Update

GlobeNewswire August 15, 2022

Unicycive Reports Key Findings from Independent Renal Dietitian Survey

GlobeNewswire July 26, 2022

Unicycive Reports Key Findings from Market Research with Nephrologists

GlobeNewswire July 20, 2022

Unicycive Announces Exclusive License and Development Agreement with Lee's Pharmaceutical Holdings Limited for Renazorb in China and Certain Other Asian Markets

GlobeNewswire July 18, 2022

CEO Clip Video Highlights How Unicycive Therapeutics is Working to Improve Quality of Life for Patients Suffering from Kidney Diseases

Newsfile June 29, 2022